BioLargo, Inc. Share Price OTC Bulletin Board
Equities
US09065A1007
Commodity Chemicals
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Transcript : BioLargo, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
04-02 | Transcript : BioLargo, Inc., Q4 2023 Earnings Call, Apr 02, 2024 |
Sales 2024 * | 19.05M 1.5B | Sales 2025 * | 25.76M 2.03B | Capitalization | 93.98M 7.4B |
---|---|---|---|---|---|
Net income 2024 * | -1M -78.74M | Net income 2025 * | - 0 | EV / Sales 2024 * | 4.93 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.65 x |
P/E ratio 2024 * |
-31.8
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.77% |
Latest transcript on BioLargo, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Dennis Calvert
CEO | Chief Executive Officer | 61 | 31/05/02 |
Charles Dargan
DFI | Director of Finance/CFO | 68 | 31/01/08 |
Chief Operating Officer | 55 | 31/05/02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Marshall
BRD | Director/Board Member | 81 | 27/04/06 |
Kenneth Code
CTO | Chief Tech/Sci/R&D Officer | 77 | 31/03/07 |
Dennis Calvert
CEO | Chief Executive Officer | 61 | 31/05/02 |
1st Jan change | Capi. | |
---|---|---|
+5.41% | 105B | |
-3.11% | 64.71B | |
+73.33% | 49.72B | |
+17.24% | 38.6B | |
+6.13% | 32.54B | |
+12.77% | 19.94B | |
+15.03% | 16.92B | |
+19.06% | 15.2B | |
+6.28% | 14.39B |